Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPIC-HR: Paxlovid in high-risk non-hospitalized COVID-19
NCT04960202Phase 3Completed
- Sponsor
- Pfizer
- Start
- Jul 2021
- Primary completion
- Dec 2021
- Modality
- Orthosteric Ligands
- Countries
- 20
01
Overview
A Phase 3 trial of Nirmatrelvir in coronavirus disease 2019 (COVID-19), sponsored by Pfizer. Started Jul 2021; status: completed.
02
Drugs
Nirmatrelvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04960202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04960202.